Search Results - "Rajpurkar, M."

Lupus anticoagulant acquired hypoprothrombinemia syndrome in childhood: two distinct patterns and review of the literature by Sarker, T., Roy, S., Hollon, W., Rajpurkar, M.

“…Introduction Lupus anticoagulant associated with acquired prothrombin deficiency also known as ‘lupus anticoagulant hypoprothrombinemia syndrome’ (LAHS) is an…”
Get full text

Factor VII and factor X deficiency in a child with a chromosome 13q duplication and deletion by Hutchins, K., Rajpurkar, M., Stockton, D. W., Callaghan, M. U.

Get full text

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006) by CHITLUR, M., WARRIER, I., RAJPURKAR, M., LUSHER, J. M.

“…Haemophilia B is an X‐linked disorder resulting in coagulation factor IX deficiency. Patients with severe deficiency (<1% factor IX activity) may have…”
Get full text

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature by Rajpurkar, M., Chitlur, M., Recht, M., Cooper, D. L.

“…Summary Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by a quantitative or qualitative defect of glycoprotein IIb/IIIa on the…”
Get full text

Transition of care for pediatric and adult patients with venous thromboembolism: A National Quality Improvement Project from the American Thrombosis and Hemostasis Network (ATHN) by DeSancho, M., Munn, J.E., Billett, H.H., Cheng, D., Holmes, C., Jaffray, J., Malone, M., Patel, K., Sharathkumar, A., Thornburg, C.D., Wang, M., Watson, C., Rajpurkar, M.

“…Transition of care (TOC) for management of anticoagulation from inpatient to outpatient setting for patients with acute venous thromboembolism (VTE) poses…”
Get full text

Results of a multinational survey of diagnostic and management practices of thromboembolic pulmonary embolism in children by Rajpurkar, M., Williams, S., Goldenberg, N.A., Van Ommen, C.H., Chan, A.K.C., Thomas, R., Biss, T.

“…The incidence of thromboembolic (TE)-pediatric pulmonary embolism (PPE) is increasing. We sought to evaluate current practice patterns and gaps in the…”
Get full text

Recommendations for future research in relation to pediatric pulmonary embolism: communication from the SSC of the ISTH by Biss, T. T., Rajpurkar, M., Williams, S., van Ommen, C. H., Chan, A. K. C., Goldenberg, N. A.

Get full text

Laboratory variability in the diagnosis of type 2 VWD variants by DiGiandomenico, Stefanie, Christopherson, Pamela A., Haberichter, Sandra L., Abshire, Thomas C., Montgomery, Robert R., Flood, Veronica H., Valentino, L., Abshire, T., Dunn, A., Bennett, C., Lusher, J., Rajpurkar, M., Hoots, W. K., Brown, D., Shapiro, A., Paola, J. Di, Lentz, S., Gill, J., Leissinger, C., Ragni, M., Hord, J., Manco‐Johnson, M., Ma, A., Boggio, L., Sharathkumar, A., Gruppo, R., Kerlin, B., Journeycake, J., Kulkarni, R., Mahoney, D, Mathias, L., Bedros, A., Diamond, C., Neff, A., Paroskie, A., DiMichele, D., Giardina, P., Cohen, A., Paidas, M., Werner, E., Matsunaga, A., Singer, T., Tarantino, M., Roberts, J., Shafer, F., Konkle, B., Cuker, A., Kouides, P., Stein, D., Manco‐Johnson, M., Dunn, A., Bennett, C., Journeycake, J., Lusher, J., Rajpurkar, M., Shapiro, A., Lentz, S., Lillicrap, D., James, P., Leissinger, C., Roberts, J., Ragni, M.

“…Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation…”
Get full text

Thromboelastography identifies children with rare bleeding disorders and predicts bleeding phenotype by Zia, A. N., Chitlur, M., Rajpurkar, M., Ozgonenel, B., Lusher, J., Callaghan, J. H., Callaghan, M. U.

“…Summary Rare bleeding disorders (RBDs) comprise 3–5% of all congenital bleeding disorders. They can evade typical coagulation screening tests and there is a…”
Get full text

Recommendations for the assessment of non‐extremity venous thromboembolism outcomes: communication from the SSC of the ISTH by Rajpurkar, M., Sharathkumar, A., Williams, S., Lau, K., Ling, S. C., Chan, A. K. C.

Get full text

Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? by CALLAGHAN, M. U., RAJPURKAR, M., CHITLUR, M., WARRIER, I., LUSHER, J.

“…Inhibitor development continues to be a major problem in the treatment of haemophilia. Immune tolerance induction (ITI) continues to be the most effective…”
Get full text

Management of intracranial surgery for refractory epilepsy in severe factor VII deficiency: choosing the optimal dosing regimen by Rajpurkar, M., Callaghan, M., Frey, M. J., Set, K., Chugani, H., Sood, S.

Get full text

Therapeutic and prophylactic ethanol lock therapy in patients with bleeding disorders by Rajpurkar, M., McGrath, E., Joyce, J., Boldt-MacDonald, K., Chitlur, M., Lusher, J.

“…Summary Obtaining a reliable venous access is a limiting factor for early initiation of clotting factor prophylaxis and immune tolerance induction. To…”
Get full text

Need for a new paediatric post thrombotic sequelae outcome measure for non-extremity thrombosis by Rajpurkar, M, Monagle, P, Massicotte, P, Chan, A

Get more information

Ethanol lock therapy for the treatment of catheter-related infections in haemophilia patients by RAJPURKAR, M., BOLDT-MACDONALD, K., MCLENON, R., CALLAGHAN, M. U., CHITLUR, M., LUSHER, J. M., BECKER, C.

“…Central venous access devices (CVAD) are increasingly being used for optimal delivery of clotting factor concentrates in patients with haemophilia with poor…”
Get full text

Crucial role for the VWF A1 domain in binding to type IV collagen by Flood, Veronica H., Schlauderaff, Abraham C., Haberichter, Sandra L., Slobodianuk, Tricia L., Jacobi, Paula M., Bellissimo, Daniel B., Christopherson, Pamela A., Friedman, Kenneth D., Gill, Joan Cox, Hoffmann, Raymond G., Montgomery, Robert R.

“…Von Willebrand factor (VWF) contains binding sites for platelets and for vascular collagens to facilitate clot formation at sites of injury. Although previous…”
Get full text

Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program by Christopherson, Pamela A., Haberichter, Sandra L., Flood, Veronica H., Perry, Crystal L., Sadler, Brooke E., Bellissimo, Daniel B., Di Paola, Jorge, Montgomery, Robert R., Abshire, T, Weiler, H, Lillicrap, D, James, P, O’Donnell, J, Ng, C, Bennett, C, Sidonio, R, Manco‐Johnson, M, Journeycake, J, Zia, A, Lusher, J, Rajpurkar, M, Shapiro, A, Lentz, S, Gill, J, Leissinger, C, Ragni, M, Tarantino, M, Roberts, J, Hord, J, Strouse, J, Ma, A, Valentino, L, Boggio, L, Sharathkumar, A, Gruppo, R, Kerlin, B, Kulkarni, R, Green, D, Hoots, K, Brown, D, Mahoney, D, Mathias, L, Bedros, A, Diamond, C, Neff, A, DiMichele, D, Giardina, P, Cohen, A, Paidas, M, Werner, E, Matsunaga, A, Shafer, F, Konkle, B, Cuker, A, Kouides, P, Stein, D

“…Background Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by the absence of von Willebrand factor (VWF). Objectives As part…”
Get full text

Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings by Goldenberg, N. A., Abshire, T., Blatchford, P. J., Fenton, L. Z., Halperin, J. L., Hiatt, W. R., Kessler, C. M., Kittelson, J. M., Manco‐Johnson, M. J., Spyropoulos, A. C., Steg, P. G., Stence, N. V., Turpie, A. G. G., Schulman, S., Punzalan, R., Wang, M., Jaffray, J., Young, G., Rajpurkar, M., Carpenter, S., Diab, Y., Verdun, N., Tarango, C., Acharya, S., Torres, M., Kucine, N., Mitchell, B., Shah, N., Thornburg, C., Takemoto, C., Kulkarni, R., O'Brien, S., Haley, K., Recht, M., Knoll, C., Thornburg, C., Geddis, A., Ahuja, S., Simpson, M., Srivaths, L., Journeycake, J., Zia, A.

“…Summary Background Randomized controlled trials (RCTs) on pediatric venous thromboembolism (VTE) treatment have been challenged by unsubstantiated design…”
Get full text

PB0649 Results from the RESIST Study for Tolerance Induction in Patients with Poor Prognosis for ITI Success by Koenigs, C., Schmidt, A., Salzmann-Manrique, E., Orlowski, A., Stichel, D., Carcao, M., Chan, A., Guerrera, M., Jeng, M., Klaassen, R., Kulkarni, R., Rajpurkar, M., Reiss, U., Sanders, J., Santagostino, E., Valentino, L., Ewing, N.

Get full text

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC) by Rajpurkar, Madhvi, Croteau, Stacy E, Boggio, Lisa, Cooper, David L

“…Recombinant activated factor VII (rFVIIa; NovoSeven RT; Novo Nordisk A/S, Bagsvaerd, Denmark) is approved in the United States for the treatment of bleeding…”
Get full text